Quantum Innovations, the cutting-edge MedTech company based in Poland, has recently secured nearly €10M (PLN 41M) in funding, marking a significant milestone in the medical technology industry. The impressive funding was spearheaded by Vinci IQ ASI, a fund established by Bank Gospodarstwa Krajowego and managed by Vinci S.A., and also received substantial participation from MedTech Holding, the company’s existing investor.
Led by Grzegorz Suwalski, M.D, PhD, Quantum Innovations has been at the forefront of developing the world’s first sensor technology for monitoring organs during surgery and transplantation. Their groundbreaking Heart Sense solution provides real-time ECG monitoring directly from the surface of a beating heart, while the Heart Guard technology is designed to monitor tissue metabolism, even in the most critical moments of cardiac surgery.
The infusion of funds will play a pivotal role in establishing a production line in a clean-room environment and obtaining necessary certifications, including regulatory and clinical trials on humans. These crucial steps are essential in expediting the product’s entry into global markets.
Przemysław Furdal, VP of quality at Quantum Innovations, emphasized, “The development of our own production line gives us the ability to quickly launch the production of sophisticated tools that can be used in more medical fields, which will further increase our market reach.”
The significance of Quantum Innovations’ work is underscored by the latest World Heart Report 2023, which revealed that over half a billion people worldwide suffer from cardiovascular diseases, accounting for nearly 20.5 million deaths, or approximately 30% of all deaths. Furthermore, a recent study by iData Research indicated that approximately 900K cardiac surgeries are performed annually in the U.S., with this number expected to rise to 1.3 million by 2029.
Piotr Woliński, President of Vinci S.A., which manages the Vinci IQ ASI fund, emphasized, “We were convinced to invest primarily by the groundbreaking product and technology, as well as the practical experience of the team. The solutions proposed by QI address an unmet need in clinical practice during cardiothoracic surgeries. Introducing these solutions into medical standards has the potential to significantly reduce complications and perioperative mortality associated with heart surgeries. Investments in medical technologies like QI fit perfectly with our fund’s mission of supporting sustainable development.”
In conclusion, Quantum Innovations’ successful funding round and the support from esteemed investors reflect the recognition of the critical importance of their pioneering work in revolutionizing cardiac surgery technology. Their innovative solutions are poised to bring about transformational changes in the medical landscape, offering new hope and opportunities for improved patient outcomes in the realm of cardiac surgery.